ClinicalTrials.gg
CompletedNCT04931563Updated May 20, 2026Results posted

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

A Phase 3 interventional study of Anifrolumab and placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 65 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
8th of 20
277 · median 159
Started
2021
with 3 others
Phase 3
9 of 20
4 open now
Registered
8th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 9 in phase 3, and was the 8th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).

Read the detailed description

This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg anifrolumab versus placebo in participants with moderate to severe, autoantibody positive SLE while receiving SOC treatment. The study will be performed in participants aged 18 to 70 years of age.

Participants with a confirmed diagnosis of moderate to severe active SLE and are currently receiving SOC comprising of oral corticosteroids (OCSs) and/or antimalarial, and/or immunosuppressants, either alone or any combination of them, for a required duration of treatment at a stable dose, as described in the inclusion criteria shall be included. Participants must have eligible scores for SLEDAI-2K, BILAG-2004, and PGA as confirmed by the DACRT.

Eligible participants will be randomised in a 1:1 ratio to receive either a fixed intravenous dose of 300 mg anifrolumab plus SOC or placebo plus SOC every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit.

03

Conditions studied

  • Active Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Aged 18 to 70 years.
  2. Body weight ≥ 40 kg.
  3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for ≥ 24 weeks.
  4. Must be receiving at least one of the following SOC regimens at screening:

    1. oral prednisone monotherapy: ≥ 7.5 mg/day and ≤ 40 mg/day, stable for > 2 weeks;
    2. (s) with or without OCS and must be stable for ≥ 8 weeks;
    3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose required.
  5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith.
  6. SLEDAI-2K score ≥ 6 points at screening and "Clinical" SLEDAI-2K score ≥4 points at both screening and Day1(randomisation), and BILAG with at least 1 level A organ system or 2 level B organ system, and PGA score ≥ 1.0 at screening.
  7. Chest imaging shows no abnormalities (unless due to SLE).
  8. No evidence or medical history of active TB, indeterminate TB should be referred to a TB specialist.
  9. All participants should use effective methods as protocol requests.
  10. Any negative SARS-CoV-2 RT-PCR test result at screening and no known or suspected COVID-19 infection or exposure within 2 weeks prior to screening and between screening and randomisation visits.

Key exclusion criteria:

  1. History or current diagnose of clinically significant non-SLE related vasculitis, severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease, catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than SLE, non-SLE disease that has required treatment of certain dosage of .
  2. History or evidence of suicidal ideation or suicidal behavior.
  3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or MTCD which has developed into SLE.
  4. History of recurrent infection requiring hospitalization and IV antibiotics, or opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization, or clinically significant chronic infection within 3 months, or recent infection still under treatment.
  5. History of immunodeficient condition, positive included.
  6. Confirmed positive, or HBcAb positive and HBV DNA detectable, or antibody positive.
  7. History of severe case of herpes zoster.
  8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks before screening.
  9. Acute COVID-19 infection or history of severe COVID-19.
  10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical cancer in situ.
  11. Female participants with abnormal pap smear results.
  12. Prior receipt of anifrolumab ,or any commercially available Janus kinase (JAK) inhibitor ≤ 12 weeks or Bruton's tyrosine kinase (BTK) inhibitor ≤ 24weeks prior to signing the ICF; any medicinal product(small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater.
  13. Known history of allergy to any component of the IP formulation or protein related products.
  14. Receipt of any of the following:

    1. Intramuscular or IV glucocorticosteroids within 6 weeks;
    2. Any live or attenuated vaccine within 8 weeks;
    3. Any restricted medication listed in protocol;
    4. Blood transfusion within 4 weeks. 15 Regular use of > 1 NSAID within 2 weeks or receipt of fluctuating doses of a NSAID within 2 weeks.

16. Certain laboratory test results requirements. 17. Concurrent enrolment in another clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19. Major surgery within 8 weeks or planned elective major surgery.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
277 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.

    Drug: placebo

  • Active comparator
    anifrolumab

    Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.

    Biological: Anifrolumab

Interventions

  • BiologicalAnifrolumab

    Intravenous infusion (IV)

  • Drugplacebo

    Intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo

    Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS)

    Time frame: Week 52

Secondary outcomes

  1. The Proportion of Participants Who Achieve SRI(4) Response at Week 52

    SRI(4) response defined by meeting all of the following criteria: * Reduction from baseline of ≥ 4 points in the SLEDAI-2K; * No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; * No worsening from baseline in the participants' lupus disease activity defined by an increase ≥0.30 points on a 3-point PGA VAS;

    Time frame: Week 52

  2. The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day

    Maintained OCS reduction defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52

    Time frame: Week 52

  3. Annualized Flare Rate Through Week 52

    Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit

    Time frame: Week 52

07

Results

Posted May 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneAnifrolumab 300mgPlacebo
Started138139
Started treatment138138
Completed118113
Not completed2026
Withdrew: Adverse event52
Withdrew: Lack of efficacy19
Withdrew: Lost to follow-up20
Withdrew: Physician decision11
Withdrew: Withdrawal by subject27
Withdrew: Due to other reasons not listed96
Withdrew: Randomised, not treated01

Outcome measures

PrimaryDifference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo

Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS)

Time frame:
Week 52
Reported as:
Count of participants · Participants
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
ParticipantsAnifrolumab 300mgPlacebo
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo8446
Statistical analysis
  • Anifrolumab 300mg vs Placebo · Bayesian analysis · p = >0.999 (Posterior probability is presented instead of nominal p-value.) · Rate difference (%): 28.4A positive posterior estimate for the treatment difference favours Anifrolumab 300mg.
SecondaryThe Proportion of Participants Who Achieve SRI(4) Response at Week 52

SRI(4) response defined by meeting all of the following criteria: * Reduction from baseline of ≥ 4 points in the SLEDAI-2K; * No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; * No worsening from baseline in the participants' lupus disease activity defined by an increase ≥0.30 points on a 3-point PGA VAS;

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Proportion of Participants Who Achieve SRI(4) Response at Week 52
ParticipantsAnifrolumab 300mgPlacebo
The Proportion of Participants Who Achieve SRI(4) Response at Week 529050
Statistical analysis
  • Anifrolumab 300mg vs Placebo · Stratified Cochran-Mantel-Haenszel · p = <0.001 (2-sided nominal p-value) · Rate difference (%): 28.8 · 95% CI 17.5 to 40.1A positive rate difference favours Anifrolumab 300mg.
SecondaryThe Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day

Maintained OCS reduction defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day
ParticipantsAnifrolumab 300mgPlacebo
The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day6543
Statistical analysis
  • Anifrolumab 300mg vs Placebo · Stratified Cochran-Mantel-Haenszel · p = 0.001 (2-sided nominal p-value) · Rate difference (%): 23.2 · 95% CI 9.3 to 37.1A positive rate difference favours Anifrolumab 300mg.
SecondaryAnnualized Flare Rate Through Week 52

Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit

Time frame:
Week 52
Reported as:
Number · Flares per person-years
Annualized Flare Rate Through Week 52
Flares per person-yearsAnifrolumab 300mgPlacebo
Annualized Flare Rate Through Week 520.220.51
Statistical analysis
  • Anifrolumab 300mg vs Placebo · Negative binomial model · p = 0.002 (2-sided nominal p-value) · Rate ratio: 0.42 · 95% CI 0.25 to 0.73Rate ratio (of Anifrolumab 300mg over Placebo) less than one favours Anifrolumab 300mg.

Adverse events

Collected over From date of first dose of investigational product throughout the treatment period up to the final clinical database locks (10JUN2025) and the safety follow-up period (until 84 days following the date of last investigational product dose). Maximum timeframe of 60 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab 300mg0/138 (0%)30/138 (21.7%)119/138 (86.2%)
Placebo0/138 (0%)17/138 (12.3%)115/138 (83.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventAnifrolumab 300mgPlacebo
PneumoniaInfections and infestations5/1382/138
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/1384/138
GastroenteritisInfections and infestations2/1380/138
Pneumonia bacterialInfections and infestations2/1380/138
Upper respiratory tract infectionInfections and infestations0/1382/138
Urinary tract infectionInfections and infestations0/1382/138
Herpes zosterInfections and infestations1/1380/138
Herpes zoster cutaneous disseminatedInfections and infestations1/1380/138
Meningitis viralInfections and infestations0/1381/138
Ophthalmic herpes zosterInfections and infestations1/1380/138
Most frequent other events
Showing 10 of 293
Most frequent other events
EventAnifrolumab 300mgPlacebo
Upper respiratory tract infectionInfections and infestations64/13851/138
Covid-19Infections and infestations20/13815/138
CoughRespiratory, thoracic and mediastinal disorders9/13813/138
Herpes zosterInfections and infestations9/1381/138
Urinary tract infectionInfections and infestations2/1389/138
HypokalaemiaMetabolism and nutrition disorders5/1389/138
PyrexiaGeneral disorders5/1389/138
NasopharyngitisInfections and infestations7/1385/138
ToothacheGastrointestinal disorders7/1381/138
GastroenteritisInfections and infestations6/1386/138

Baseline characteristics

The full analysis set (FAS): All participants randomized into the study who receive at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(Years)Anifrolumab 300mgPlaceboTotal
Mean36.2 ± 9.736.1 ± 9.836.1 ± 9.8
Age, Customized
Age, Customized(Participants)Anifrolumab 300mgPlaceboTotal
Age group — >=18 to <65 years137137274
Age group — >=65 years112
Sex: Female, Male
Sex: Female, Male(Participants)Anifrolumab 300mgPlaceboTotal
Female128126254
Male101222
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anifrolumab 300mgPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino138138276
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Anifrolumab 300mgPlaceboTotal
American Indian or Alaska Native000
Asian138138276
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

65 sites
  • Research Site
    Baoding, 071000, China
  • Research Site
    Baotou, 014010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100144, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Binzhou, 256603, China
  • Research Site
    Changchun, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chuangchun, 130012, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510260, China
  • Research Site
    Guilin, 541001, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Jieyang, 522000, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Jining, 272011, China
  • Research Site
    Kunming, 650032, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Linyi, 276003, China
  • Research Site
    Luoyang, 471003, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchong, 637000, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Nanyang, 473005, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shengyang, 110004, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Shijiazhuang, 050001, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Ürümqi, 831118, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuxi, 214002, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Xinxiang, 453002, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zaozhuang, 277102, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Hong Kong, 00000, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Davao City, PH-8000, Philippines
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Lipa City, 4217, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Quezon City, 1112, Philippines
  • Research Site
    Gwangju, 501-757, South Korea
  • Research Site
    Seoul, 04763, South Korea
  • Research Site
    Seoul, 6591, South Korea
  • Research Site
    Suwon, 16499, South Korea
  • Research Site
    Kaohsiung City, 81362, Taiwan
  • Research Site
    New Taipei City, 220, Taiwan
  • Research Site
    New Taipei City, 23561, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 11220, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, 10400, Thailand
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Apr 2025, 42 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Jun 18, 2021
StartActual
Sep 13, 2021
Primary completionActual
Apr 7, 2025
CompletionActual
Jun 10, 2025
Results first posted
May 20, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04931563
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Sep 13, 2021
Primary completion
Apr 7, 2025
Completion
Jun 10, 2025
Results posted
May 20, 2026
Last update
May 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion